POM-V Prescription Required

Luteoplan 250 micrograms/ml Solution for Injection for Cattle and Horses

Active ingredient: Cloprostenol

Form

Injection

Species

Cattle Horses

Manufacturer

Syn Vet-Pharma Ireland Limited

VMD MA No.

54400/3000

What it's used for

- - corpus luteum. - - - Horses (mares): - -

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Cloprostenol

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Luteoplan 250 micrograms/ml Solution for Injection for Cattle and Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

-
-
corpus luteum.
-
-
-
Horses (mares):
-
-

Cattle (cows and heifers):
One dose equals 500 micrograms of cloprostenol per animal, corresponding to 2 ml of
the veterinary medicinal product.
Oestrus induction and synchronisation:
Administer one dose per animal. When no oestrus symptoms are observed, a second
dose can be administered after 11 days.
Treatment of clinical and subclinical endometritis in the presence of a functional corpus
luteum:
Administer one dose per animal. If necessary, repeat the treatment 10-14 days later.
Treatment of ovarian luteal cysts:
Administer a single dose per animal.
Induction of parturition:
Administer a single dose per animal, not earlier than 10 days before the expected date
of calving.
Induction of abortion up to day 150 of gestation:
Administer a single dose per animal, between the 5
th
and the 150
th
day of gestation.
Horses (mares):
Ponies and horses weighing less than 500 kg bodyweight:
One dose equals 125 – 250 micrograms of cloprostenol per animal, corresponding to
0.5 – 1 ml of the veterinary medicinal product.
Horses weighing more than 500 kg bodyweight:
One dose equals 250 – 500 micrograms of cloprostenol per animal, corresponding to
1 – 2 ml of the veterinary medicinal product.
Oestrus induction and synchronisation:
Administer a single dose per animal.
Termination of early gestation between day 5 and day 120:
Administer a single dose per animal, not earlier than 5 days after ovulation.
The stopper may be safely punctured up to 10 times. When treating groups of animals
in one run, use a draw-off needle that has been placed in the vial stopper to avoid
excess broaching of the stopper. The draw-off needle should be removed after
treatment.

Do not use in pregnant animals in which the induction of abortion or parturition is not
intended.
Do not administer to induce parturition in animals with suspected dystocia due to
mechanical obstruction or abnormal position, presentation and/or posture of the foetus.
Do not use in animals with compromised cardiovascular function, bronchospasm or
gastrointestinal dysmotility.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Cattle (cows and heifers):
Rare
(1 to 10 animals / 10,000
animals treated):
Injection site infection
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylaxis
;
Increased respiratory rate
;
Increased heart rate
;
Abdominal pain
, Diarrhoea
3,5
;
Incoordination
;
Lying down
;
Retained placenta
, Metritis
, Dystocia
,
Stillbirth
;
Restlessness, Frequent urination
3,5
;
May occur if anaerobic bacteria enter the injection site, especially following
intramuscular injection, and may become generalized. Aggressive antibiotic therapy,
particularly covering clostridial species, should be employed at the first sign of
infection. Careful aseptic techniques should be employed to decrease the possibility
of these infections.
Requiring immediate medical attention. Can be life-threatening.
Cloprostenol may cause effects similar to Prostaglandin
muscles.
May be caused by induction of parturition or abortion. As part of induction of
parturition, depending on the date of treatment versus the date of conception, the
incidence of placental retention may be increased.
In case of occurrence, these effects are observed within 15 minutes post-injection
and usually disappear after one hour.
Horses (mares):
Uncommon
(1 to 10 animals / 1,000
animals treated):
Abnormal oestrus
;Rare
(1 to 10 animals / 10,000
animals treated):
Injection site infection
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylaxis
;
Increased respiratory rate
;
Increased heart rate
;
Increased sweating
4,5
;
Abdominal pain
, Colic
, Diarrhoea
4,8
;
Incoordination
, Muscle tremor
;
Lying down
, Decreased body temperature
;
Retained placenta
, Metritis
, Dystocia
,
Stillbirth
;
Restlessness, Frequent urination
4,8
;
Haemorrhagic (anovular) follicles and multiple ovulations are reported in literature
for horses treated with cloprostenol.
May occur if anaerobic bacteria enter the injection site, especially following
intramuscular injection, and may become generalized. Aggressive antibiotic therapy,
particularly covering clostridial species, should be employed at the first sign of
infection. Careful aseptic techniques should be employed to decrease the possibility
of these infections.
Requiring immediate medical attention. Can be life-threatening.
Cloprostenol may cause effects similar to Prostaglandin
muscles.
Appears to be transient and resolves without any treatment.
Mild.
May be caused by termination of gestation, depending on the date of treatment
versus the date of conception, the incidence of placental retention may be increased.
In case of occurrence, these effects are observed within 15 minutes post-injection
and usually disappear after one hour.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

There is a refractory period of several days after ovulation (e.g. four to five days in
cattle and horses), when females are insensitive to the luteolytic effect of
prostaglandins.
For the termination of gestation in cattle, best results are obtained before day 100 of
gestation. Results are less reliable between day 100 and 150 of gestation.

Special precautions for safe use in the target species:
To reduce the risk of anaerobic infections arising from vasoconstriction at the injection
site, injections into contaminated (wet or dirty) skin areas should be avoided.
Thoroughly clean and disinfect injection sites prior to administration.
Do not administer intravenously.
All animals should receive adequate supervision after treatment.
Induction of parturition or abortion may cause dystocia, stillbirth and/or metritis. The
incidence of retained placenta may be increased depending on the time of treatment
relative to the date of conception.
Injection into adipose tissue can result in incomplete absorption of the veterinary
medicinal product.
Cloprostenol may cause effects related to Prostaglandin
muscles, such as increased frequency of urination and defecation.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Prostaglandins of the type, such as cloprostenol, may be absorbed through the
skin and may cause bronchospasm or miscarriage. Care should be taken when
handling the veterinary medicinal product to avoid self-injection or skin contact.
Pregnant women, women of childbearing age, asthmatics and persons with other
respiratory tract diseases should avoid contact when handling this veterinary medicinal
product. Personal protective equipment consisting of impervious gloves should be
worn when handling the veterinary medicinal product.
Accidental spillage on the skin should be washed immediately with soap and water. If
accidental contact with eyes occurs, rinse the affected eyes thoroughly with clean,
fresh water. In case of accidental self-injection or spillage onto the skin seek medical
advice immediately, particularly as shortness of breath may occur, and show the
package leaflet or label to the physician.
Chlorocresol may cause irritation and allergic reactions. People with known
hypersensitivity to chlorocresol should administer the veterinary medicinal product with
caution.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

The concomitant use of oxytocin and cloprostenol increases the effects on the uterus.
The concomitant use of progestogens decreases the effect of cloprostenol.
Do not administer with non-steroidal anti-inflammatory drugs (NSAIDs) since they
inhibit endogenous prostaglandin synthesis.

This veterinary medicinal product does not require any special temperature storage
conditions.
This veterinary medicinal product should be stored upright.

Cattle:
Meat and offal: 1 day.
Milk: Zero hours.
Horses:
Meat and offal: 2 days.
Milk: 24 hours.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.